XML 45 R28.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail) - Astellas Agreement [Member] - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | 35 Months Ended | 45 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Apr. 30, 2006 | Jun. 30, 2005 | Jun. 30, 2020 | Jun. 30, 2020 | Feb. 28, 2009 | Feb. 28, 2009 | Dec. 31, 2019 | Jun. 30, 2019
Japan [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Upfront, non-contingent and time-based payments received |  |  |  |  |  | $ 40.1 |  |
Potential milestone payments |  | $ 132.5 |  |  |  |  |  |
Commercial sales milestone |  | 15.0 |  |  |  |  |  |
Additional consideration based on net sales description |  |  |  | low 20% range |  |  |  |
Aggregate consideration received |  |  | $ 90.1 | $ 90.1 |  |  |  |
Japan [Member] | Clinical and Development Milestone [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Potential milestone payments |  | 22.5 |  |  |  |  |  |
Japan [Member] | Regulatory Milestone [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Potential milestone payments |  | $ 95.0 |  |  |  |  |  |
Europe [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Upfront, non-contingent and time-based payments received |  |  |  |  | $ 320.0 |  |  |
Additional consideration based on net sales description |  |  |  | low 20% range |  |  |  |
Aggregate consideration received |  |  | 540.0 | $ 540.0 |  |  |  |
Development and regulatory approval milestones | $ 425.0 |  |  |  |  |  |  |
Percentage of joint development costs committed to fund | 50.00% |  |  |  |  |  |  |
Transaction price and allocated to performance obligations |  |  |  |  |  |  |  | $ 130.0
Revenue during period from performance obligations |  |  | 0.6 | $ 0.6 |  |  | $ 128.8 |
Milestone payment received |  |  | $ 130.0 |  |  |  |  |
Europe [Member] | Clinical and Development Milestone [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Potential milestone payments | $ 90.0 |  |  |  |  |  |  |
Europe [Member] | Regulatory Milestone [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Potential milestone payments | $ 335.0 |  |  |  |  |  |  |

X
- Definition The amount of additional consideration based on net sales of product as defined under a collaboration agreement. + References No definition available. + Details
Name: | fgen_AdditionalConsiderationBasedOnNetSales
Namespace Prefix: | fgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of aggregate consideration receivable under collaborative arrangement. + References No definition available. + Details
Name: | fgen_CollaborativeArrangementAggregateConsideration
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the amount of milestone payments related to commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_CommercialSalesMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement. + References No definition available. + Details
Name: | fgen_DevelopmentAndRegulatoryApprovalMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs. + References No definition available. + Details
Name: | fgen_PercentageOfFundingForCosts
Namespace Prefix: | fgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_PotentialMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Transaction price allocated to performance obligations. + References No definition available. + Details
Name: | fgen_TransactionPriceAllocatedToPerformanceObligations
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |